Benjamin H. Lowentritt, MD, FACS, Discusses How 18F-rhPSMA-7.3 PET Expands the Armamentarium for Suspected Recurrent Prostate Cancer

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin H. Lowentritt, MD, FACS, director of Minimally Invasive Surgery and Robotics; director of the Prostate Cancer Care Program, Chesapeake Urology, Baltimore, Maryland; and president of the American Urological Association, MidAtlantic Region, spoke with CancerNetwork^® about how an analysis of the phase 3 SPOTLIGHT study (NCT04186845), assessing 18F-rhPSMA-7.3 in subgroups of patients with suspected recurrent prostate cancer, adds to the existing diagnostic tools for this patient population.

Transcript:

The great part about the SPOTLIGHT study is that it’s adding to the armamentarium that we have for diagnosis and eventually treatment of prostate cancer. [18F-rhPSMA-7.3] is an agent that seems to have the potential for less bladder uptake; it’s a little bit less excreted in the urine and accumulates less in the bladder. The hope would be that it would allow for a very clear picture within the bladder when there’s something to be found there. It continues to add to the options that we have and the hope that this will be available clinically in the future. It’s very promising to have more and more options.

Reference

Lowentritt, B. Impact of Clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.